Skip to content

Weight Loss and Abdominal Fat Responses to Different Diet Compositions

Weight Loss and Visceral Fat Responses to Different Diet Compositions

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01034046
Enrollment
100
Registered
2009-12-17
Start date
2009-04-30
Completion date
2011-06-30
Last updated
2010-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Metabolic Syndrome, Obesity

Keywords

Obesity

Brief summary

The purpose of this study is to assess the effectiveness of two different reduced calorie diets that have different combinations of carbohydrate, fat, and protein content in 2 groups of study participants: insulin sensitive participants and insulin resistant participants. The hypothesis of the study is that people with high and low levels of insulin resistance may respond differently to different diet compositions in a real-world environment using meals that are commonly available.

Interventions

OTHERLow Carbohydrate Diet

Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.

OTHERLow Fat Diet

Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.

Sponsors

Jenny Craig, Inc.
CollaboratorINDUSTRY
University of Nevada, Las Vegas
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Females between 18 and 65 years of age. * BMI 30-40 kg/m2 * Stable weight within 10 lb (+/-) for last 2 months

Exclusion criteria

* Pregnant or lactating. * Must not currently be part of a structured weight loss program * Taking a medication for diabetes (such as insulin, metformin, glyburide, glipizide, Byetta, pioglitazone, or rosiglitazone) or a medication such as systemic glucocorticoids that are known to affect blood sugar or blood insulin. * Beck Depression Inventory (BDI Score \>19 and/or positively endorses the suicide question on the BDI-II) * Taking any chronic medication that has not had a stable dose for 1 month or longer. * Diabetes mellitus defined as a fasting glucose ≥ 126 mg/dL on screening. * Taking medications or dietary supplements that cause weight gain or weight loss (eg. antipsychotics (Seroquel, Zyprexa, and Risperdal) and/or anorectics). * Clinically significant laboratory abnormalities at the opinion of the investigators. * History of Bariatric Surgery * A history of: * Type 2 diabetes, type 1 diabetes, or diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g. Cushing's syndrome and acromegaly. * Liver disease, such as cirrhosis, or chronic active hepatitis B or C. * Use of investigational drugs within 30 days of visit 1 * A pacemaker. * Hospitalization for depression in the past 6 months, history of moderate to severe major depression. * Any other condition that in the investigators' or sponsor's opinion could interfere with the results of the trial.

Design outcomes

Primary

MeasureTime frame
Change in weight in kg24 weeks

Secondary

MeasureTime frame
Change in visceral fat via bioimpedance24 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026